Baxter International Inc. (BAX)

Over the past six months, Baxter International Inc. (BAX) stock has experienced a 4.88% increase, but over the last year, the stock has shown a -10.04% decrease. As of June 25, 2025, the share price was $30.61, representing a decline of 9.71% from $33.90 on June 26, 2024. Baxter reported its first-quarter 2025 results on May 1, 2025, with net sales increasing to $2,625 million, but gross margin and operating income decreased. Baxter declared a quarterly dividend on May 6, 2025. Baxter was scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on May 27, 2025. On June 24, 2025, Baxter published its annual Corporate Responsibility Report. The market has revised upward the revenue expectations for Baxter International Inc. for FY2025, with forecasts adjusted by 1.54% over the past three months. Baxter significantly reduced its debt by repaying approximately $2.8 billion in the fourth quarter of 2023. Baxter is focused on spinning off its kidney care division by early 2025. The acquisition of Hillrom in late 2021 increased Baxter's leverage substantially. The sudden departure of CEO Joe Almeida has led to an interim CEO. New US tariffs may put pressure on Baxter to reach its profit goals.

Demand for Baxter's products and services is largely dependent on overall demand in the healthcare market and can vary in response to economic conditions, regulatory requirements, seasonality, natural disasters, wars, acts of terrorism, pandemics, and epidemics. The healthcare market's increased focus on asset and resource efficiency, along with reimbursement constraints and competitive dynamics, have led to declining margins for some products.

Baxter International Inc. is a global healthcare company specializing in the development, manufacturing, and marketing of medical devices and medications for healthcare professionals. The company operates within the Healthcare sector, specifically in the Medical Instruments & Supplies industry. Baxter's product portfolio includes medicines and medical devices, kidney dialysis drugs and equipment, systems for delivering medications and intravenous (IV) therapy, hospital and clinical care technologies, and pharmaceuticals.

Baxter International operates in over 110 countries with manufacturing facilities in 27 countries. As of 2023, Baxter operates in 115 countries worldwide with a comprehensive global distribution strategy. In 2022, 52% of revenue came from the United States, 22% from Europe, 18% from Asia-Pacific, and 8% from other regions. The company also has a strong presence in North American healthcare markets, capturing approximately 32% market share in critical care and renal care product segments.

Baxter's brand reputation is generally associated with quality and reliability in the healthcare industry, but it has been impacted by supply chain vulnerabilities, cost management issues, and the effects of natural disasters. The company faces scrutiny regarding its corporate responsibility commitments and the execution of acquisitions, such as Hillrom. The divestiture of the kidney care division has also affected investor perception.

Baxter International Inc. is primarily owned by institutional shareholders, who hold 94.75% of the company, while insiders own 16.02% and retail investors own 0.00%. Top institutional holders include BlackRock, Inc., Vanguard Group Inc, Dodge & Cox, Pzena Investment Management Llc, State Street Corp, and Price T Rowe Associates Inc /md/. Third Point LLC is identified as the largest individual Baxter International shareholder, owning 76.86 million shares, representing 14.98% of the company.